報價延遲最少15分鐘:2025/07/03 06:19 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
326.03 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
13.10/13.13
|
|
企業價值
9.35B
|
| 資產負債 |
|
每股賬面淨值
20.65
|
| 現金流量 |
|
現金流量率
0.06
|
| 損益表 |
|
收益
2.11B
|
|
每股收益
61.98
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/03 06:19 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018. |